Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Die Diabetologie
Erschienen in: Die Diabetologie 2/2019

22.02.2019 | Typ-2-Diabetes | DDG Praxisempfehlungen

Therapie des Typ-2-Diabetes

verfasst von: Rüdiger Landgraf, Monika Kellerer, Jens Aberle, Eva-Maria Fach, Baptist Gallwitz, Andreas Hamann, Hans-Georg Joost, Harald Klein, Dirk Müller-Wieland, Michael A. Nauck, Hans-Martin Reuter, Stephan Schreiber, Erhard Siegel

Erschienen in: Die Diabetologie | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://​www.​deutsche-diabetes-gesellschaft.​de/​ueber-uns.​html) befinden sich unter „Leitlinien > Praxisempfehlungen“ alle PDFs zum kostenlosen Download. …
Literatur
1.
2.
Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the Metabolic Syndrome. Circulation 120:1640–1645PubMedCrossRef
3.
Wang R, Song Y, Yan Y et al (2016) Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: A meta-analysis. Atherosclerosis 254:193–199PubMedCrossRef
4.
Lawall H, Huppert P, Rümenapf G et al (2015) Periphere arterielle Verschlusskrankheit (PAVK), Diagnostik, Therapie und Nachsorge. AWMF, Register Nr, S 65–3
5.
6.
7.
8.
Roeb E, Steffen HM (2015) Bantel H et al. S2k Leitlinie: Nicht-alkoholische Fettlebererkrankungen. AWMF, Register Nr, S 21–25
9.
10.
11.
12.
Heinemann L, Kaiser P, Freckmann G et al (2018) HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose? Diabetologie 13:46–53CrossRef
13.
Nauck M, Petermann A, Müller-Wieland D et al (2018) Definition, Klassifikation und Diagnostik des Diabetes Mellitus. Diabetologie 13((Suppl. 2):S90–S96
14.
Landgraf R, Nauck M, Freckmann G et al (2018) Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen? Dtsch Med Wochenschr. Im Druck
15.
16.
Kempf K, Altpeter B, Berger J et al (2017) Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: A randomized controlled trial. Diabetes Care 40((7):863–871PubMedCrossRef
17.
Lean MEJ, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, clusterrandomised trial. Lancet 391:541–551PubMedCrossRef
18.
Adipositas–Prävention und Therapie. AWMF Register Nr. 050–001
19.
20.
The Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145–154PubMedCentralCrossRef
21.
Unick JL, Gaussoin SA, Hill JO et al (2017) Objectively assessed physical activity and weight loss maintenance among individuals enrolled in a lifestyle intervention. Obesity (Silver Spring) 25((11):1903–1909CrossRef
22.
Gregg EW, Lin J, Bardenheier B et al (2018) Impact of Intensive Lifestyle Intervention on Disability-Free Life Expectancy: The LookAHEAD Study. Diabetes Care 41:1040–1048PubMedCrossRefPubMedCentral
23.
24.
Lazarus B, Wu A, Shin JI et al. Association of metformin use with risk of lactic acidosis across the range of kidney function. A community-based cohort tudy. JAMA Intern Med. 2018. published online June 4
25.
Griffin SJ, Leaver JK, Irving GJ et al (2017) Impact of metformin on cardiovascular disease: a meta-analysis of randomised trails among people with type 2 diabetes. Diabetologia 60:1620–1629PubMedPubMedCentralCrossRef
26.
Palmer SC, Mavridis D, Nicolucci A et al (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 316((3):313–324PubMedCrossRef
27.
Mallik R, Chowdhury TA (2018) Metformin in cancer. Diabetes Res Clin Pract 2018 May 26. pii: S0168-8227(17)31410-9
28.
Rados DV, Pinto LC, Remonti LR et al (2016) The association between sulfonylurea use and all-cause and cardiovascular mortality: A meta-analysis with trial sequential analysis of randomized clinical trials. Plos Med 13(6):e1002091PubMedPubMedCentralCrossRef
29.
Azoulay L, Suissa S (2017) Sulfonylureas and the risks of cardiovascular events and death: A methodological meta-regression analysis of the observational studies. Diabetes Care 40:706–714PubMedCrossRef
30.
Bain S, Druyts E, Balijepalli C et al (2017) Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes Obes Metab 19((3):329–335PubMedCrossRef
31.
Zhuang XD, He X, Yang DY et al (2018) Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network metaanalysis of 166371 participants from 170 randomized controlled trials. Cardiovasc Diabetol 17 (1:79CrossRef
32.
Powell WR, Christiansen CL, Miller DR (2018) Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments. Diabetes Ther. Publ Online May 28
33.
Chen K, Kang D, Yu M et al (2018) Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials. Diabetes Obes Metab 20:1029–1033PubMedCrossRef
34.
Simpson SH, Lee J, Choi S et al (2015) Mortality risk among sulfonylureas: ansystematic review and network meta-analysis. Lancet Diabetes Endocrinol 3((1):43–51PubMedCrossRef
35.
Fadini GP, Bottigliengo D, D’Angelo F et al (2018) Comparative Effectiveness of DPP4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. Diabetes Ther. Publ Online June 1
36.
Wang F, He Y, Zhang R et al (2017) Combination therapy of metformin plus dipeptidylpeptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients. Systematic review and meta-analysis. Medicine 96(36):e7638PubMedPubMedCentralCrossRef
37.
Hemmingsen B, Schroll JB, Lund SS et al (2013) Sulphonylureamonotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 30(4):CD9008 (Apr)
38.
Hemmingsen B, Schroll JB, Jorn Wetterslev J et al (2014) Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2((3):E162–E175PubMedPubMedCentralCrossRef
39.
Sharma M, Beckley N, Nazareth I et al (2017) Effectiveness of sitagliptin compared to sulfonylureas for type 2 diabetes mellitus inadequately controlled on metformin: a systematic review and meta-analysis. BMJ Open 7:e17260PubMedPubMedCentralCrossRef
40.
Chen K, Kang D, Yu M et al (2018) Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A meta-analysis of long-term randomized controlled trials. Diabetes Obes Metab 20:1029–1033PubMedCrossRef
41.
Monami M, Ahrén B, Dicembrini I et al (2013) Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15:112–120PubMedCrossRef
42.
Xu S, Zhang X, Tang L et al (2017) Cardiovascular effects of dipeptidylpeptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review. Postgrad Med 129:205–215PubMedCrossRef
43.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-causemortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 319((15):1580–1591PubMedPubMedCentralCrossRef
44.
Li L, Li S, Deng K et al (2016) Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMJ 352:i610PubMedPubMedCentralCrossRef
45.
Guo WQ, Li L, Su Q et al (2017) Effect of dipeptidylpeptidase-4 inhibitors on heart failure: A Network Meta-Analysis. Value Health 20:1427–1430PubMedCrossRef
46.
Filion KB, Azoulay L, Platt RW et al (2016) A Multicenter Observational Study of Incretin-based Drugs and Heart Failure. N Engl J Med 374:1145–1154PubMedCrossRef
47.
Liu J, Li L, Deng K et al (2017) Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 357:j2499PubMedPubMedCentralCrossRef
48.
Nyström T, Bodegard J, Nathanson D et al (2017) Second line initiation of insulin compared with DPP4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia. Diabetes Res Clin Pract 123:199–208PubMedCrossRef
49.
Tkáč I, Raz I (2017) Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 40:284–286PubMedCrossRef
50.
Abrahami D, Douros A, Yin H et al (2018) Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 360:k872PubMedPubMedCentralCrossRef
51.
Storgaard H, Gluud LL, Bennett C et al (2016) Benefits and Harms of Sodium- Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS ONE 11(11):e166125PubMedPubMedCentralCrossRef
52.
Müller-Wieland D, Kellerer M, Cypryk K et al (2018) Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. Publ Online Jun 27
53.
Aronson R, Frias J, Goldman A et al (2018) Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab 20:1453–1460PubMedPubMedCentralCrossRef
54.
Pratley RE, Eldor R, Raji A et al (2018) Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab 20:1111–1120PubMedPubMedCentralCrossRef
55.
Fadini GP, Bonora BM, Avogaro A (2017) SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia 60:1385–1389PubMedCrossRef
56.
Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376:2300–2303PubMedCrossRef
57.
Monami M, Nreu B, Zannoni S et al (2017) Effects of SGLT2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract 130:53–60PubMedCrossRef
58.
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373:2117–2128CrossRefPubMed
59.
Kosiborod M, Cavender MA, Fu AZ et al (2017) Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs. CVD-REAL study. Circulation 136:249–259PubMedPubMedCentralCrossRef
60.
Wanner C, Inzucchi SE, Zinman B (2016) Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 375:323–334PubMedCrossRef
61.
Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5:610–621PubMedCrossRef
62.
Sattar N, McLaren J, Kristensen SL et al (2016) SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339PubMedPubMedCentralCrossRef
63.
Ferrannini E, Mark M, Mayoux E et al. CV Protection in the EMPA-REG OUTCOME Trial (2016) A „Thrifty Substrate“ Hypothesis. Diabetes Care 39:1108–1114PubMedCrossRef
64.
65.
Neal B, Perkovic V, Mahaffey KW et al (2017) CANVAS Program Collaborative Group Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 377:644–657PubMedCrossRef
66.
Ryan PB, Buse JB, Schuemie MJ et al (2018) Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). Diabetes Obes Metab :1–13
67.
Sonesson C, Johansson PA, Johnsson E et al (2016) Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol 15:37PubMedPubMedCentralCrossRef
68.
Toulis KA, Willis BH, Marshall T et al (2017) All-cause mortality in patients with diabetes under treatment with dapagliflozin: A Population-based, opencohort study in the health improvement network database. J Clin Endocrinol Metab 102:1719–1725PubMedCrossRef
69.
Persson F, Nystrom T, Jorgensen ME et al (2018) Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab 20:344–351PubMedCrossRef
70.
Nystrom T, Bodegard J, Nathanson D et al (2017) Novel oral glucose lowering drugs are associated with lower risk of all-causemortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes Obes Metab 19:831–841PubMedPubMedCentralCrossRef
71.
Wu JH, Foote C, Blomster J et al (2016) Effects of sodium-glucose cotransporter- 2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and metaanalysis. Lancet Diabetes Endocrinol 4:411–419PubMedCrossRef
72.
73.
Scheen AJ (2018) Does lower limb amputation concern all SGLT2 inhibitors? Nat Rev Endocrinol 14((6):326–328PubMedCrossRef
74.
75.
Inzucchi SE, Iliev H, Pfarr E et al (2018) Empagliflozin and assessment of lower limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41:e4–e5PubMedCrossRef
76.
Kohler S, Kaspers S, Salsali A et al (2018) Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo- Controlled Trials and a Head-to-Head Study Versus Glimepiride. Diabetes Care. Publ Online June 15
77.
Levin PA, Nguyen H, Wittbrodt ET et al (2017) Glucagon-like peptide-1 receptor agonists: a. Syst Rev Comp Eff Res 10:123–139
78.
Zinman B, Marso SP, Christiansen E et al (2018) Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care 41((8):1783–1791PubMedCrossRef
79.
80.
Nauck MA, Tornøe K, Rasmussen S et al (2018) Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diab Vasc Dis Res. Publ Online June 1
81.
Verma S, Bhatt DL, Bain SC et al (2018) Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease. Circulation 137((20):2179–2183PubMedCrossRef
82.
Marso SP, Nauck MA, Monk Fries T et al (2018) Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the LEADER Trial). Am J Cardiol 121:1467–1470PubMedCrossRef
83.
Mann JFE, Ørsted DD, Buse JB (2017) Liraglutide and Renal Outcomes in Type 2 Diabetes. N Engl J Med 377:839–848PubMedCrossRef
84.
Mahmoud AN, Saad M, Mansoor H et al (2017) Cardiovascular safety of incretin- based therapy for type 2 diabetes: A meta-analysis of randomized trials. Int J Cardiol 230:324–326PubMedCrossRef
85.
Ferdinand KC, Botros FT, Atisso CM et al (2016) Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol 15:38–50PubMedPubMedCentralCrossRef
86.
Home PD, Ahrén B, Reusch JEB et al (2017) Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Longterm efficacy with or without rescue therapy. Diabetes Res Clin Pract 131:49–60PubMedCrossRef
87.
Ahrén B, Carr MC, Murphy K et al (2017) Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. Diabetes Res Clin Pract 126:230–239PubMedCrossRef
88.
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377((13):1228–1239PubMedCrossRef
89.
Bethel MA, Patel RA, Merrill P et al (2018) Cardiovascular outcomes with glucagon- like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105–113PubMedCrossRef
90.
Pratley RE, Aroda VR (2018) Lingvay I et SUSTAIN 7 investigators. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSS164 TAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 6((4):275–286PubMedCrossRef
91.
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375((19):1834–1844PubMedCrossRef
92.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-causemortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 319((15):1580–1591PubMedPubMedCentralCrossRef
93.
Dicembrini I, Nreu B, Scatena A et al (2017) Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 54:933–941PubMedCrossRef
94.
Monami M, Nreu B, Scatena A et al (2017) Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes Obes Metab 19((9):1233–1241PubMedCrossRef
95.
Azoulay L, Filion KB, Platt RW et al (2016) Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis. Jama Intern Med 176((10):1464–1473PubMedCrossRef
96.
Wang T, Wang F, Gou Z et al (2015) Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1324515 patients from observational studies. Diabetes Obes Metabol 17:32–41CrossRef
97.
Russell-Jones D, Pouwer F, Khunti K (2018) Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab 20:488–496PubMedCrossRef
98.
Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. New Engl J Med 377((8):723–732PubMedCrossRef
99.
Pieber TR, Marso SP (2018) McGuire DK et al. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes andmortality. Diabetologia 61:58–65PubMedCrossRef
100.
Lau IT, Lee KF, So WY et al (2017) Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes Metab Syndr Obes 10:273–284PubMedPubMedCentralCrossRef
101.
Ritzel R, Roussel R, Giaccari A et al (2018) Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‑year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab 20:541–548PubMedCrossRef
102.
Bonadonna RC, Renard E, Cheng A et al (2018) Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? Diabetes Res Clin Pract 142:19–25PubMedCrossRef
103.
Linnebjerg H, Lam EC, Seger ME et al (2015) Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963 016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies. Diabetes Care 38:2226–2233PubMedCrossRef
104.
Rosenstock J, Hollander P, Bhargava A et al (2015) Similar efficacy and safety of LY2963 016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (ELEMENT 2 study). Diabetes Obes Metabol 17:734–741CrossRef
105.
Yamada T, Kamata R, Ishinohachi K et al (2018) Biosimilar vs originator insulins: Systematic review and meta-analysis. Diabetes Obes Metab 20:1787–1792PubMedCrossRef
106.
But A, De Bruin ML, Bazelier MT et al (2017) Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia 60:1691–1703PubMedPubMedCentralCrossRef
107.
Gentile S, Fusco A, Colarusso S et al (2018) A randomized, open-label, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin U‑100 versus concentrated lispro insulin U‑200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. Expert Opin Drug Saf 17((5):445–450PubMedCrossRef
108.
Heise T, Hövelmann U, Brøndsted L et al (2015) Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metabol 17:682–688CrossRef
109.
Bowering K, Case C, Harvey J et al (2017) Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. Diabetes Care 40((7):951–957PubMedCrossRef
110.
Maiorino MI, Chiodini P, Bellastella G et al (2017) Insulin and Glucagon-Like Peptide1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Care 40:614–624PubMedCrossRef
111.
Guja C, Frías JP, Somogyi A et al (2018) Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. Diabetes Obes Metab 20:1602–1614PubMedPubMedCentralCrossRef
112.
Rodbard HW, Lingvay I, Reed J et al (2018) Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): A randomized, controlled trial. J Clin Endocrinol Metab 103((6):2291–2301PubMedPubMedCentralCrossRef
113.
The SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373:2103–2116
114.
Düsing R (2017) Therapieziele bei der Hypertoniebehandlung. Dtsch Med Wochenschr 142:1420–1429PubMedCrossRef
115.
Banegas JR, Ruilope LM, de la Sierra A et al (2018) Relationship between clinic and ambulatory blood-pressure measurements and mortality. n Engl J Med 378:1509–1520PubMedCrossRef
116.
Khunti K, Gomes MB, Pocock S et al (2018) Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. Diabetes Obes Metab 20:427–437PubMedCrossRef
117.
Gough SC, Bode B, Woo V et al (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26- week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabet. Endocrinol 2(11):885–893
118.
Diamant M, Nauck MA, Shaginian R et al (2014) Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diabetes Care 37((10):2763–2773PubMedCrossRef
119.
Ahmann A, Rodbard HW, Rosenstock J et al (2015) Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebocontrolled trial. Diabetes Obes Metab 17:1056–1064PubMedPubMedCentralCrossRef
120.
Montvida O, Klein K, Kumar S et al (2017) Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients. Diabetes Obes Metab 19((1):108–117PubMedCrossRef
121.
Billings LK, Doshi A, Gouet D et al (2018) Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial. Diabetes Care 41((5):1009–1016PubMedCrossRef
122.
Catapano AL (2016) GrahamI, De Backer G et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 37(39):2999–3058PubMedCrossRef
123.
124.
125.
Landgraf R, Klauss V, Middeke M et al 2017 Perioperatives Management von Menschen mit Diabetes bei elektiven Eingriffen. Review. Teil 1. Diabetologe. 13:203–218; Teil 2. Diabetologe 2017 13:277–290CrossRef
Metadaten
Titel
Therapie des Typ-2-Diabetes
verfasst von
Rüdiger Landgraf
Monika Kellerer
Jens Aberle
Eva-Maria Fach
Baptist Gallwitz
Andreas Hamann
Hans-Georg Joost
Harald Klein
Dirk Müller-Wieland
Michael A. Nauck
Hans-Martin Reuter
Stephan Schreiber
Erhard Siegel
Publikationsdatum
22.02.2019
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 2/2019
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-019-0459-7

Weitere Artikel der Ausgabe 2/2019

Die Diabetologie 2/2019 Zur Ausgabe

Journal Club

Optimale Insulinkorrektur bei Typ-1-Diabetes nach intensiver körperlicher Belastung

DDG Praxisempfehlungen

Therapie des Typ-1-Diabetes

Mitteilungen des BDI

Mitteilungen des BDI

Leitthema

Daten aus den Praxen: Komorbiditäten bei Typ‑2-Diabetes

Journal Club

Auswirkungen von Hypoglykämien auf kardiovaskuläre Ereignisse

Magazin

Magazin

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft. 

Zu den Praxisempfehlungen
Bildnachweise